To assess the risk of myocardial infarction (MI), stroke or death in new users of IVT aflibercept versus new users of IVT ranibizumab in real-world practice
Latest Information Update: 15 Sep 2021
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration; Diabetic macular oedema
- Focus Adverse reactions
- 15 Sep 2021 New trial record
- 25 Aug 2021 Results presented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management